A Pilot Study of Long‐Term Weekly Interferon‐β Administration for Chronic Hepatitis B

Tatehiro Kagawa, Toshio Morizane, Hidetsugu Saito, Satoshi Tsunematsu, Shinichirou Tada, Naoki Kumagai, Kanji Tsuchimoto, Hitoshi Sugiura, Makio Mukai, Masaharu Tsuchiya

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

Interferon‐β was given weekly for 24 wk, at a dose of 3 million units, intravenously, to 10 patients with chronic hepatitis B who were serologically positive for HBsAg and HBeAg. Their condition was followed for 6 months after the end of therapy. Both serum hepatitis B virus‐associated DNA‐polymerase activity and alanine aminotransferase level became significantly lower during therapy and during the 6 months after the end of therapy than at the beginning of therapy. In five of 10 patients, the seroconversion from HBeAg positive to anti‐HBe positive had occurred by 6 months after the end of therapy, and in four of these five patients, serum alanine aminotransferase level became normal. Weekly interferon‐β administration over 6 months seems effective in inducing seroconversion and in normalizing serum alanine aminotransferase level.

Original languageEnglish
Pages (from-to)212-216
Number of pages5
JournalThe American Journal of Gastroenterology
Volume88
Issue number2
DOIs
Publication statusPublished - 1993 Feb

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'A Pilot Study of Long‐Term Weekly Interferon‐β Administration for Chronic Hepatitis B'. Together they form a unique fingerprint.

Cite this